Results 221 to 230 of about 119,037 (316)

Liver Transplantation After Combination Therapy Based on Immune Checkpoint Inhibitors: A Multicenter Retrospective Study of Safety and Efficacy

Organ Medicine, EarlyView.
This multicenter retrospective study assessed preoperative immune checkpoint inhibitor (ICI) therapy in 17 hepatocellular carcinoma patients undergoing liver transplantation. All received at least one cycle of ICI‐based combination therapy before transplant and achieved a 76.5% objective response rate.
Huanquan Chen, Tianxing Dai, Jie Gao, Chuanjiang Li, Huanwei Chen, Feiwen Deng, Nan Ma, Guoying Wang   +7 more
wiley   +1 more source

Multifrequency Multiparameter Magnetic Resonance Elastography Applied to an In Vivo Porcine Model for Assessing Portal Hypertension

Portal Hypertension &Cirrhosis, EarlyView.
Portal hypertension, a critical complication in chronic liver disease, has long relied on invasive hepatic venous pressure gradient measurement for definitive diagnosis. This study establishes that multifrequency three‐dimensional magnetic resonance elastography (3D‐MRE) can noninvasively quantify portal pressure, with splenic stiffness and loss ...
Bai Du, Xiaolong Qi, Yujia Ma, Chen Pan, Qijun Wu, Meng Niu, Yu Shi   +6 more
wiley   +1 more source

Genetic drivers of liver cirrhosis: The role of SERPINA1 and PNPLA3 variants in disease onset and progression. [PDF]

PLoS One
Holinka M, Frankova S, Adamcova Selcanova S, Skladany L, Fabian O, Kveton M, Merta D, Adamkova V, Hubacek JA, Pitova V, Vesela S, Hucl T, Jirsa M, Sperl J.   +13 more
europepmc   +1 more source

[Experimental hepatitis and liver cirrhosis].

Terapevticheskii arkhiv, 2003
openaire   +1 more source

The Use of Non‐Selective Beta‐Blockers in Cirrhotic Portal Hypertension

Portal Hypertension &Cirrhosis, EarlyView.
Non‐selective beta‐blockers (NSBBs) reduce portal pressure and play a key role in preventing variceal bleeding, managing ascites, and preventing hepatocellular carcinoma (HCC) in cirrhotic patients. Their clinical application requires individualized strategies and further optimization of indications. ABSTRACT Liver cirrhosis is the end stage of various
Tong Bu, Tianyuan Yang, Qi Wang
wiley   +1 more source

Polyunsaturated fatty acids as a potential preventive and therapeutic intervention for metabolic dysfunction-associated steatotic liver disease and its progression to hepatocellular carcinoma. [PDF]

Front Nutr
Kouti T, Christodoulou P, Christodoulides S, Protopapa F, Michaeloudes C, Farazi PA.   +5 more
europepmc   +1 more source

Factors Associated With Liver Fibrosis in Patients With Type 2 Diabetes and the Predictive Value of CHI3L1

Portal Hypertension &Cirrhosis, EarlyView.
In a retrospective cohort of 236 patients with type 2 diabetes (T2DM), metabolic dysfunction‐associated steatotic liver disease (MASLD) was common and significant fibrosis (liver stiffness measurement [LSM] ≥8 kPa) was frequently observed. Serum chitinase‐3‐like protein 1 (CHI3L1) correlated with LSM (r = 0.48) and remained an independent predictor of ...
Lixia Sun, Shuangshuang Du, Aili Fan, Jiawen Feng, Fei Wang, Jia Lian, Jie Zhang, Baoxin Qian, Qing Ye   +8 more
wiley   +1 more source

SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope? [PDF]

Life (Basel)
Brusnic O, Onisor DM, Boicean A, Porr C, Sofonea FD, Anderco P, Ichim C.   +6 more
europepmc   +1 more source

The Safety of Interferon‐Based Therapies in Chronic Hepatitis B Patients With Compensatory Cirrhosis

Portal Hypertension &Cirrhosis, EarlyView.
While nucleos(t)ide analog (Nuc) therapy is the standard for chronic hepatitis B, pegylated interferon‐alpha (Peg‐IFN‐α) provides unique advantages, including finite treatment duration and long‐term benefits. However, its use in patients with compensated cirrhosis remains limited due to persistent safety concerns about potential decompensation and ...
Qiran Zhang, Taoran Geng, Ruirui You, Huiling Xiang, Ying Guo, Xiaohong Gao, Guojun Li, Qun Zhang, Xiaoping Wu, Haifang Cao, Wenhua Zhang, Jia Shang, Jiawei Geng, Lihong Qu, Shuilin Sun, Xiulan Xue, Rui Zhao, Lihua Zhong, Guohong Ge, Yanbin Wang, Jianqi Lian, Ming Liang, Qing Ye, Xiaoyan Wang, Xiaoqing Guo, Dan Xu, Yiqi Yu, Feng Sun, Chao Qiu, Jiming Zhang, Yuxian Huang, Wenhong Zhang, Xiaolong Qi   +32 more
wiley   +1 more source

CX3CL1/CX3CR1 axis in liver disease: context-dependent roles and balance. [PDF]

Front Immunol
Liu J, Guo Z, Zheng X.
europepmc   +1 more source